David Knox Biography and Net Worth

CFO of Hyperion DeFi

David Knox brings with him extensive expertise in scaling capital markets strategies and financial services businesses. He joins Hyperion DeFi from PayPal, where he served as Head of Capital Markets and Head of Finance for Global Credit and Financial Services. In his dual role at PayPal, he led the profitable expansion of the company’s lending segments under a “balance sheet light” strategic imperative and managed core FP&A responsibilities with rigorous governance and reporting across the PayPal and Venmo global financial services platforms.

Earlier in his career, Mr. Knox was Director at Cantor Fitzgerald, where he provided capital markets structuring and advisory services across mortgage-backed and asset-backed finance transactions. He also held prior roles in lending and capital markets at SoFi, Hudson Advisors, and the Royal Bank of Scotland. Mr. Knox holds a bachelor’s degree from the University of Connecticut and is an alumnus of the Harvard Business School.

What is David R. Knox's net worth?: The estimated net worth of David R. Knox is at least $1.30 million as of December 31st, 2025. Mr. Knox owns 327,950 shares of Hyperion DeFi stock worth more than $1,295,403 as of September 22nd. This net worth approximation does not reflect any other assets that Mr. Knox may own. Learn More about David R. Knox's net worth.
How do I contact David R. Knox?: The corporate mailing address for Mr. Knox and other Hyperion DeFi executives is 3090 Nowitzki Way, Suite 300, Dallas, TX, 75219. Hyperion DeFi can also be reached via phone at (833) 393-6684 and via email at [email protected]. Learn More on David R. Knox's contact information.
Has David R. Knox been buying or selling shares of Hyperion DeFi?: David R. Knox has not been actively trading shares of Hyperion DeFi during the last quarter. Most recently, on Wednesday, December 31st, David R. Knox bought 27,950 shares of Hyperion DeFi stock. The stock was acquired at an average cost of $3.59 per share, with a total value of $100,340.50. Following the completion of the transaction, the chief financial officer now directly owns 327,950 shares of the company's stock, valued at $1,177,340.50. Learn More on David R. Knox's trading history.
Who are Hyperion DeFi's active insiders?: Hyperion DeFi's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), David Knox (CFO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Hyperion DeFi's active insiders.
Are insiders buying or selling shares of Hyperion DeFi?: In the last twelve months, Hyperion DeFi insiders bought shares 11 times. They purchased a total of 197,204 shares worth more than $641,026.94. The most recent insider tranaction occured on June, 2nd when insider Hyunsu Jung bought 1,000 shares worth more than $3,660.00. Insiders at Hyperion DeFi own 7.5% of the company. Learn More about insider trades at Hyperion DeFi.
Information on this page was last updated on 6/2/2026.

David R. Knox Insider Trading History at Hyperion DeFi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/31/2025	Buy	27,950	$3.59	$100,340.50	327,950

David R. Knox Buying and Selling Activity at Hyperion DeFi

Hyperion DeFi Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $4.00

$3.83

$4.05

50 Day Range

MA: $3.03

$2.34

$3.92

2 Week Range

Now: $4.00

$2.34

$11.89

Volume

506,151 shs

Average Volume

468,653 shs

Market Capitalization

$62.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53